Audentes Therapeutics to Present at Upcoming Investor Conferences

SAN FRANCISCO, Sept. 19, 2017 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the following upcoming investor conferences:

• LEERINK Partners Roundtable Series: Rare Disease & Immuno-OncologySeptember 27, 2017, 11:30 am ETLotte New York Palace, New York, NY
• Chardan Inaugural Gene Therapy ConferenceOctober 10, 2017, 10:45 am ETWestin Grand Central Hotel, New York, NY

To access a live webcast of the presentations, please visit the Events & Presentations page within the Investors + Media section of the Audentes website.  Replays of live webcasts will be available on the Audentes website for approximately 30 days following the conferences.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  We have four product candidates in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:Thomas Soloway, CFO415.818.1040[email protected]

Media Contact:Paul Laland415.519.6610[email protected]

View original content with multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-to-present-at-upcoming-investor-conferences-300521721.html

SOURCE Audentes Therapeutics, Inc.